Compare AU
Compare WXOZ vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the SPDR S&P World Ex Australia Carbon Aware ETF (WXOZ) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
WXOZ | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 11 | 78 |
Median incremental investment | $993.75 | $640.11 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,252.80 | $1,274.70 |
Average age group | > 35 | > 35 |
Key Summary
WXOZ | CURE | |
|---|---|---|
Strategy | WXOZ.AX was created on 2013-03-18 by SPDR. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 411.75m in AUM and 784 holdings. The SPDR S&P World ex Australia Carbon Aware ETF seeks to closely track, before fees and expenses, the returns of the S&P Developed Ex-Australia LargeMidCap Carbon Aware Index. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 27.78m in AUM and 125 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Apple Inc (5.03 %) Microsoft Corp (4.21 %) NVIDIA Corp (3.45 %) | Natera Inc (2.70 %) Vertex Pharmaceuticals Inc (2.67 %) Alnylam Pharmaceuticals Inc (2.64 %) |
Top 3 industries | Information Technology (57.51 %) Communication Services (14.24 %) Consumer Discretionary (6.87 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (66.13 %) Japan (8.26 %) United Kingdom of Great Britain and Northern Ireland (4.57 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.07 % | 0.45 % |
Key Summary
WXOZ | CURE | |
|---|---|---|
Issuer | SPDR | Global X |
Tracking index | S&P Developed ex Australia LargeMidCap AUD Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.07 % | 0.45 % |
Price | $46.40 | $42.49 |
Size | $416.010 million | $28.994 million |
10Y return | 80.97 % | N/A |
Annual distribution yield (5Y) | 5.73 % | 4.24 % |
Market | ASX | ASX |
First listed date | 19/03/2013 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
WXOZ | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 11 | 78 |
Median incremental investment | $993.75 | $640.11 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,252.80 | $1,274.70 |
Average age group | > 35 | > 35 |
Pros and Cons
WXOZ | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
WXOZ | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |